5 Mar 2024 • Evidence on the bleeding risk associated with low-density lipoprotein cholesterol (LDL-C) levels in patients receiving dual antiplatelet therapy (DAPT) remains sparse.

In patients with minor ischemic stroke (MIS) or high-risk transient ischemic attack (HRTIA) receiving DAPT, LDL-C levels below 70 mg/dL were associated with an increased bleeding risk within three months, as per findings published in JAMA Neurology.

This heightened risk was observed primarily in patients on ticagrelor-aspirin (aHR, 1.71), whereas those on clopidogrel-aspirin did not exhibit a significant association between LDL-C levels and bleeding risk.

Source: JAMA | Read full story